NASDAQ:CRMD CorMedix (CRMD) Stock Price, News & Analysis $7.39 -0.07 (-0.94%) Closing price 04:00 PM EasternExtended Trading$7.39 +0.00 (+0.05%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About CorMedix Stock (NASDAQ:CRMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CorMedix alerts:Sign Up Key Stats Today's Range$7.33▼$7.5550-Day Range$7.10▼$8.6152-Week Range$6.13▼$13.02Volume1.42 million shsAverage Volume930,198 shsMarket Capitalization$575.98 millionP/E Ratio3.93Dividend YieldN/APrice Target$15.00Consensus RatingModerate Buy Company Overview CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing products designed to prevent and treat infectious and inflammatory diseases. The company’s lead product is DefenCath® (taurolidine and heparin), an antimicrobial catheter-lock solution intended to reduce the risk of catheter-related bloodstream infections in adult patients with kidney failure who receive chronic hemodialysis through a central venous catheter. The U.S. Food and Drug Administration approved DefenCath in 2023. The product is used to fill and lock the lumens of dialysis catheters between treatment sessions, helping protect against infection while maintaining catheter patency. CorMedix markets DefenCath in the United States and is focused on expanding its use within the U.S. dialysis-care market. CorMedix was founded in 2006 and is headquartered in Berkeley Heights, New Jersey. The company continues to evaluate additional applications for its taurolidine-based technology and related opportunities in infection prevention and other high-risk healthcare settings. David Mehalick serves as CorMedix’s president and chief executive officer.AI Generated. May Contain Errors. Read More CorMedix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreCRMD MarketRank™: 3.08775161163 of 5 starsCorMedix scored higher than 62% of companies evaluated by MarketBeat, and ranked 352nd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingCorMedix has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialCorMedix has a consensus price target of $15.00, representing about 103.0% upside from its current price of $7.39.Amount of Analyst CoverageCorMedix has only been the subject of 3 research reports in the past 90 days.Read more about CorMedix's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-74.07% Earnings GrowthEarnings for CorMedix are expected to decrease by -74.07% in the coming year, from $0.54 to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is 3.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is 3.45, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.97.Price to Earnings Growth RatioCorMedix has a PEG Ratio of 1.37. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CorMedix's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.50% of the float of CorMedix has been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 18.9, which indicates bearish sentiment.Change versus previous monthShort interest in CorMedix has recently decreased by 4.81%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. News and Social Media4.0 / 5News SentimentN/A News SentimentCorMedix has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for CorMedix this week, compared to 5 articles on an average week.Search Interest12 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat Follows3 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock.Percentage Held by Insiders3.50% of the stock of CorMedix is held by insiders.Percentage Held by Institutions34.18% of the stock of CorMedix is held by institutions.Read more about CorMedix's insider trading history. Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRMD Stock News HeadlinesReviewing CorMedix (NASDAQ:CRMD) and Eyepoint Pharmaceuticals (NASDAQ:EYPT)October 4, 2026 | americanbankingnews.comCorMedix Inc (NASDAQ:CRMD) Stock Has Consensus Target Price of $15.00October 3, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 13 at 1:00 AM | Profits Run (Ad)Oppenheimer initiates coverage of CorMedix at outperformSeptember 23, 2026 | msn.comOppenheimer avvia la copertura di CorMedix con rating outperformSeptember 23, 2026 | it.investing.comCorMedix出席富国银行第21届年度医疗健康大会：增长与风险并存September 10, 2026 | cn.investing.comCorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely BudgedSeptember 7, 2026 | finance.yahoo.comCorMedix Therapeutics to Participate in the Wells Fargo Healthcare ConferenceSeptember 1, 2026 | globenewswire.comSee More Headlines CRMD Stock Analysis - Frequently Asked Questions How have CRMD shares performed this year? CorMedix's stock was trading at $11.63 at the beginning of 2026. Since then, CRMD shares have decreased by 36.5% and is now trading at $7.39. How were CorMedix's earnings last quarter? CorMedix Inc (NASDAQ:CRMD) announced its earnings results on Thursday, August, 13th. The company reported $0.29 EPS for the quarter, topping analysts' consensus estimates of $0.24 by $0.05. The business had revenue of $101.93 million for the quarter, compared to the consensus estimate of $96.04 million. CorMedix had a trailing twelve-month return on equity of 40.52% and a net margin of 40.49%. Read the conference call transcript. When did CorMedix's stock split? CorMedix shares reverse split on Tuesday, March 26th 2019.The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Is CorMedix doing a stock buyback? CorMedix's board approved a stock buyback program on Monday, February 2nd 2026, which authorizes the company to repurchase $75,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 12.3% of its shares through open market purchases. Shares buyback programs are often a sign that the company's leadership believes its shares are undervalued. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), Alibaba Group (BABA), Palantir Technologies (PLTR) and Qualcomm (QCOM). Company Calendar Last Earnings8/13/2026Today10/13/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CRMD's financial health is in the Red zone, according to TradeSmith. CRMD has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CRMD CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees191Year Founded2006Price Target and Rating Average Price Target for CorMedix$15.00 High Price Target$19.00 Low Price Target$13.00 Potential Upside/Downside+103.0%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$2.14 Trailing P/E Ratio3.93 Forward P/E Ratio13.69 P/E Growth1.38Net Income$163.05 million Net Margins40.49% Pretax Margin44.00% Return on Equity40.52% Return on Assets20.61% Debt Debt-to-Equity Ratio0.31 Current Ratio2.56 Quick Ratio2.36 Sales & Book Value Annual Sales$311.71 million Price / Sales1.85 Cash Flow$2.02 per share Price / Cash Flow3.65 Book Value$5.14 per share Price / Book1.44Miscellaneous Outstanding Shares77,940,000Free Float75,216,000Market Cap$575.98 million OptionableOptionable Beta1.40 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:CRMD) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
